Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)

Conditions:   NSCLC;   EGFR T790M;   FDG-PET Intervention:   Drug: Osimertinib Sponsor:   Martin Schuler, Prof. Dr. med. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials